On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Brain Scientific Inc. (BRSF) Receives First Purchase Order from Department of Veterans Affairs 

  • First order marks a significant milestone as Veterans Affairs runs the largest integrated healthcare system in the country
  • BRSF hopes the relationship will bring cutting-edge brain diagnostics to a nationwide network of veterans’ health care
Brain Scientific (OTCQB: BRSF), a commercial-stage, neurology-focused medical device and software company, has announced the start of working with the U.S. Department of Veterans Affairs – VA Medical Centers, which placed the first purchase order of NeuroCap(TM) for one of its hospitals (https://ibn.fm/p3rw0). This move represents a significant milestone because the U.S. Department of Veterans Affairs runs the country’s largest integrated healthcare system. “Our team at Brain Scientific is proud to start what it hopes will be a long-term relationship to serve patient needs at VA Medical Centers and do our part to help reduce risk factors for both patients and staff. Our disposable EEG NeuroCap diminishes the potential for cross-contamination, HAI, and exposure for staff members and patients. Sanitation is a major concern for hospitals and is even more crucial in COVID-19 times as neurodiagnostic teams are urged to find alternatives to reusable products,” said Amy Griffith, vice president of strategy and business development for Brain Scientific. NeuroCap is BRSF’s flagship product, a pre-gelled disposable EEG headset targeting the growing demand for better yet cost-efficient brain monitoring. The need for this disposable and portable device is especially pronounced in the current pandemic environment, which has seen an increasing demand for EEG testing. Since more than 80% of hospitalized COVID-19 patients present with neurological symptoms, rapid EEG testing is becoming critical. This is where Brain Scientific’s NeuroCap enters the picture. Designed for quick application (video of the NeuroCap setup is available here) while also allowing for minimal exposure to patients, NeuroCap appears to be a perfect fit for the current environment where medical professionals are facing a contagious virus. The traditional bulky EEG equipment is complicated to clean between uses and is cumbersome to apply. Even after cleaning, microscopic traces of tissue debris and bacteria may remain on reusable EEG electrodes. This is where NeuroCap makes a difference. Designed for single use, this disposable device helps ensure that the virus is not spread through equipment. The innovative headset also contributes to limiting person-to-person exposure because it is applied quickly and effortlessly, decreasing virus transmission potential between medical staff and patient. Aligned with the international system, NeuroCap features 19 channels and 22 electrodes to produce high-quality study results. Also, NeuroCap is compatible with most existing EEG amplifiers on the market. With this first VA order, Brain Scientific brings this revolutionary brain diagnostics technology to Veterans Health Care, the nation’s most extensive health-care system. Veterans Health Care provides care at 1,255 health-care facilities, including 170 VA Medical Centers and 1,074 outpatient sites that serve more than 9 million veterans (https://ibn.fm/bEdHT). Committed to developing cutting-edge technologies to revolutionize brain diagnostics, Brain Scientific appears to be on the right track to tackle some of neurology’s most pressing diagnostics challenges and narrow the widening gap of accessibility to neurological care across the country. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

From Our Blog

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

April 24, 2024

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping […]

Rotate your device 90° to view site.